文献速递浆细胞疾病淋巴瘤

IgM型多发性骨髓瘤主要为生发中心前疾病,且具有不同于华氏巨球蛋白血症的独特基因组与转录组特征

IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
PubMed 文献 · Blood · 2021-01-01

本研究通过全基因组和转录组测序分析IgM型多发性骨髓瘤(IgM-MM)样本,旨在区分其与非IgM型多发性骨髓瘤及华氏巨球蛋白血症(WM)。结果表明IgM-MM共享多发性骨髓瘤的大部分结构变异和基因表达特征,但具有t(11;14)易位、6号和13号染色体缺失等关键特征,且易位断点主要由VHDHJH重组而非类别转换区引起,支持生发中心前起源。此外,IgM-MM中CD20、布鲁顿酪氨酸激酶表达升高及BCL2/BCL2L1比值高,为靶向治疗提供潜力。

要点

  • IgM-MM具有t(11;14)易位及6号、13号染色体缺失等独特基因组特征。
  • IgM-MM易位断点主要为VHDHJH重组诱导,缺乏类别转换,支持生发中心前起源。
  • IgM-MM中CD20、布鲁顿酪氨酸激酶表达升高,BCL2/BCL2L1比值高,为潜在靶点。

核心结论

  • IgM-MM与非IgM-MM共享大部分定义性结构变异和基因表达谱,但具有独特的分子和转录因子特征,且不同于WM。

研究设计与样本

  • 研究对IgM-MM样本进行全基因组和转录组测序,以识别其与非IgM-MM及WM的鉴别特征。

主要发现

  • IgM-MM具有t(11;14)易位、6号和13号染色体缺失以及独特的分子和转录因子特征。
  • IgM-MM易位断点主要由VHDHJH重组诱导,而非通常的类别转换区断点,且缺乏类别转换,支持生发中心前起源。
  • IgM-MM中CD20和布鲁顿酪氨酸激酶表达升高,BCL2/BCL2L1比值高。

关键数值与推荐

  • IgM-MM的易位断点以VHDHJH重组诱导为主,区别于类别转换区断点。
  • IgM-MM中CD20和布鲁顿酪氨酸激酶表达升高,BCL2/BCL2L1比值高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunoglobulin M (IgM) multiple myeloma (MM) is a rare disease subgroup. Its differentiation from other IgM-producing gammopathies such as Waldenström macroglobulinemia (WM) has not been well characterized but is essential for proper risk assessment and treatment. In this study, we investigated genomic and transcriptomic characteristics of IgM-MM samples using whole-genome and transcriptome sequencing to identify differentiating characteristics from non-IgM-MM and WM. Our results suggest that IgM-MM shares most of its defining structural variants and gene-expression profiling with MM, but has some key characteristics, including t(11;14) translocation, chromosome 6 and 13 deletion as well as distinct molecular and transcription-factor signatures. Furthermore, IgM-MM translocations were predominantly characterized by VHDHJH recombination-induced breakpoints, as opposed to the usual class-switching region breakpoints; coupled with its lack of class switching, these data favor a pre-germinal center origin. Finally, we found elevated expression of clinically relevant targets, including CD20 and Bruton tyrosine kinase, as well as high BCL2/BCL2L1 ratio in IgM-MM, providing potential for targeted therapeutics.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bazarbachi AH, Avet-Loiseau H, Szalat R, et al. IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021. PMID: 34792571. doi:10.1182/blood.2021011452

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。